Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nefazodone and depression.

W V Vieweg1

  • 1Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0710, USA.

Drugs of Today (Barcelona, Spain : 1998)
|January 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical students' attitudes toward sexual contact with patients and supervisors.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
Same author

Polydipsia-hyponatraemia syndrome : epidemiology, clinical features and treatment.

CNS drugs·2013
Same author

Musical hallucinations induced by propranolol.

The Journal of nervous and mental disease·1998
Same author

Measuring and estimating daily urine volume in psychiatric patients: strengths and weaknesses.

Schizophrenia research·1998
Same author

The Charles Bonnet syndrome: a review.

The Journal of nervous and mental disease·1997
Same author

Auditory hallucinations and agenesis of the left internal carotid artery.

The Journal of neuropsychiatry and clinical neurosciences·1996
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Nefazodone, a novel antidepressant, effectively treats depression and related anxiety by targeting serotonin receptors. It offers improved sleep and fewer side effects like sexual dysfunction or withdrawal symptoms compared to other antidepressants.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Nefazodone represents a fourth-generation antidepressant.
  • It exhibits unique serotonergic mechanisms of action.

Purpose of the Study:

  • To elucidate the pharmacological profile of nefazodone.
  • To highlight its therapeutic applications and side effect profile.

Main Methods:

  • Pharmacological analysis of synaptic receptor interactions.
  • Clinical observations on efficacy and tolerability.

Main Results:

  • Nefazodone potently antagonizes 5-HT(2) receptors and moderately blocks 5-HT reuptake.
  • It demonstrates efficacy in treating depression and associated anxiety.

Related Experiment Videos

  • The drug shows a low incidence of sexual dysfunction and withdrawal syndrome.
  • Nefazodone improves sleep efficiency and reduces nighttime awakenings.

    • Conclusions:

    • Nefazodone is a well-tolerated antidepressant with a favorable side effect profile.
    • Its distinct mechanism offers benefits for depression, anxiety, and sleep disturbances.